HUP0203486A2 - Véralvadással összefüggő betegségek megelőzése és kezelése - Google Patents
Véralvadással összefüggő betegségek megelőzése és kezeléseInfo
- Publication number
- HUP0203486A2 HUP0203486A2 HU0203486A HUP0203486A HUP0203486A2 HU P0203486 A2 HUP0203486 A2 HU P0203486A2 HU 0203486 A HU0203486 A HU 0203486A HU P0203486 A HUP0203486 A HU P0203486A HU P0203486 A2 HUP0203486 A2 HU P0203486A2
- Authority
- HU
- Hungary
- Prior art keywords
- prevention
- treatment
- animal
- tissue factor
- human tissue
- Prior art date
Links
- 230000002265 prevention Effects 0.000 title abstract 6
- 201000010099 disease Diseases 0.000 title abstract 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 4
- 230000023555 blood coagulation Effects 0.000 title 1
- 101000635804 Homo sapiens Tissue factor Proteins 0.000 abstract 4
- 238000010171 animal model Methods 0.000 abstract 3
- 206010020608 Hypercoagulation Diseases 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 230000003027 hypercoagulation Effects 0.000 abstract 2
- 230000002085 persistent effect Effects 0.000 abstract 2
- 229940124597 therapeutic agent Drugs 0.000 abstract 2
- 201000005665 thrombophilia Diseases 0.000 abstract 2
- 206010003178 Arterial thrombosis Diseases 0.000 abstract 1
- 241001465754 Metazoa Species 0.000 abstract 1
- 206010047249 Venous thrombosis Diseases 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 210000004102 animal cell Anatomy 0.000 abstract 1
- 210000004204 blood vessel Anatomy 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 230000003449 preventive effect Effects 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 230000008719 thickening Effects 0.000 abstract 1
- 210000004881 tumor cell Anatomy 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0271—Chimeric vertebrates, e.g. comprising exogenous cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5094—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for blood cell populations
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/15—Humanized animals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/106—Primate
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Environmental Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Veterinary Medicine (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biodiversity & Conservation Biology (AREA)
- Animal Husbandry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Ecology (AREA)
- Plant Pathology (AREA)
- Public Health (AREA)
Abstract
A találmány olyan állatra vonatkozik, amelyben tartós hiperkoagulációsállapot áll fenn, és amelyet úgy hoz létre, hogy kísérleti állatba,például egérbe állati sejtet, például tumorsejtet ültetetnek, amelybehumán szöveti faktort kódoló gén lett inszertálva, és a sejtetszaporodni hagyják, ezáltal biztosítják a humán szöveti faktorfolyamatos utánpótlását a kísérleti állatban. Az állati modellalkalmas kutatási célokra, és tartós hiperkoagulációs állapottaljellemzett betegségek megelőzésére/kezelésére alkalmas terápiás szerekkifejlesztésére. A találmány tárgyát képezik továbbá preventív vagyterápiás szerek tartós hiperkoagulációs állapottal jellemzettbetegségek megelőzésére/kezelésére; fertőzések következtében kialakulóhiperkoagulációs állapot megelőzésére/kezelésére; vénás trombózisés/vagy artériás trombózis megelőzésére/kezelésére; vagy az érfalközépső rétegének megvastagodása következtében kialakuló betegségekmegelőzésére/kezelésére, amelyek aktív hatóanyagként humán szövetifaktor (humán TF) elleni ellenanyagot tartalmaznak. Ó
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP28216799 | 1999-10-01 | ||
JP28213499 | 1999-10-01 | ||
JP28212099 | 1999-10-01 | ||
JP28184399 | 1999-10-01 | ||
JP28219299 | 1999-10-01 | ||
JP28218899 | 1999-10-01 | ||
PCT/JP2000/006802 WO2001024626A1 (fr) | 1999-10-01 | 2000-09-29 | Prevention et traitement de maladies associees a la coagulation sanguine |
Publications (1)
Publication Number | Publication Date |
---|---|
HUP0203486A2 true HUP0203486A2 (hu) | 2003-02-28 |
Family
ID=27554423
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HU0203486A HUP0203486A2 (hu) | 1999-10-01 | 2000-09-29 | Véralvadással összefüggő betegségek megelőzése és kezelése |
Country Status (18)
Country | Link |
---|---|
US (2) | US8062638B1 (hu) |
EP (2) | EP2351483A1 (hu) |
JP (1) | JP3859512B2 (hu) |
KR (1) | KR20030008205A (hu) |
AT (1) | ATE498305T1 (hu) |
AU (1) | AU7450600A (hu) |
BR (1) | BR0014667A (hu) |
CA (1) | CA2388408A1 (hu) |
CZ (1) | CZ20021035A3 (hu) |
DE (1) | DE60045638D1 (hu) |
DK (1) | DK1222854T3 (hu) |
HU (1) | HUP0203486A2 (hu) |
IL (1) | IL148980A0 (hu) |
MX (1) | MXPA02003278A (hu) |
NO (1) | NO20021410L (hu) |
PL (1) | PL354961A1 (hu) |
SK (1) | SK4442002A3 (hu) |
WO (1) | WO2001024626A1 (hu) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6703494B2 (en) | 2000-03-16 | 2004-03-09 | Genentech, Inc. | Anti-tissue factor antibodies with enhanced anticoagulant potency |
JPWO2002078738A1 (ja) * | 2001-03-26 | 2004-10-07 | 鈴木 宏治 | 血液レオロジー改善剤 |
ATE488135T1 (de) | 2001-05-18 | 2010-12-15 | Chugai Pharmaceutical Co Ltd | Menschlichen gewebefaktor produzierendes nichtmenschliches knock-in -tier |
JP2005512970A (ja) * | 2001-10-02 | 2005-05-12 | ノボ ノルディスク アクティーゼルスカブ | ヒト組織因子抗体 |
EP1550455A1 (en) * | 2002-05-23 | 2005-07-06 | Chugai Seiyaku Kabushiki Kaisha | Agent neutralizint tissue factor inhibitor and agent neutralizing activated blood coagulation factor viii preparation |
KR101235507B1 (ko) | 2003-02-28 | 2013-02-20 | 추가이 세이야쿠 가부시키가이샤 | 단백질을 함유하는 안정화 제제 |
US7605235B2 (en) | 2003-05-30 | 2009-10-20 | Centocor, Inc. | Anti-tissue factor antibodies and compositions |
EP1939218A1 (en) * | 2006-12-29 | 2008-07-02 | Thrombotargets Europe, S.L. | Microvesicles derived from recombinant yeast having haemostatic activities and uses thereof |
US8722044B2 (en) | 2011-03-15 | 2014-05-13 | Janssen Biotech, Inc. | Human tissue factor antibody and uses thereof |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS58201994A (ja) | 1982-05-21 | 1983-11-25 | Hideaki Hagiwara | 抗原特異的ヒト免疫グロブリンの生産方法 |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
IE81149B1 (en) | 1987-02-12 | 2000-05-03 | Genentech Inc | Methods and deoxyribonucleic acid for the preparation of tissue factor protein |
US5223427A (en) | 1987-03-31 | 1993-06-29 | The Scripps Research Institute | Hybridomas producing monoclonal antibodies reactive with human tissue-factor glycoprotein heavy chain |
EP0321526A1 (en) * | 1987-06-12 | 1989-06-28 | Mount Sinai School Of Medicine Of The City University Of New York | Cloning and expression of human tissue factor |
DE69127627T2 (de) | 1990-08-29 | 1998-02-19 | Genpharm Int | Produktion und Nützung nicht-menschliche transgentiere zur Produktion heterologe Antikörper |
AU668349B2 (en) | 1991-04-25 | 1996-05-02 | Chugai Seiyaku Kabushiki Kaisha | Reconstituted human antibody against human interleukin 6 receptor |
US5346991A (en) * | 1991-06-13 | 1994-09-13 | Genentech, Inc. | Tissue factor mutants useful for the treatment of myocardial infarction and coagulopathic disorders |
AU3328493A (en) | 1991-12-17 | 1993-07-19 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
WO1994002602A1 (en) | 1992-07-24 | 1994-02-03 | Cell Genesys, Inc. | Generation of xenogeneic antibodies |
US5648267A (en) | 1992-11-13 | 1997-07-15 | Idec Pharmaceuticals Corporation | Impaired dominant selectable marker sequence and intronic insertion strategies for enhancement of expression of gene product and expression vector systems comprising same |
US5879677A (en) * | 1992-12-09 | 1999-03-09 | The Scripps Research Institute | Method for inhibition of cerebral tissue factor mediated reperfusion damage |
CA2161351C (en) | 1993-04-26 | 2010-12-21 | Nils Lonberg | Transgenic non-human animals capable of producing heterologous antibodies |
KR100261941B1 (ko) | 1994-07-13 | 2000-07-15 | 나가야마 오사무 | 사람의 인터루킨-8에 대한 재구성 사람항체 |
JP3865418B2 (ja) | 1994-07-13 | 2007-01-10 | 中外製薬株式会社 | ヒトインターロイキン−8に対する再構成ヒト抗体 |
EP1978033A3 (en) | 1995-04-27 | 2008-12-24 | Amgen Fremont Inc. | Human antibodies derived from immunized xenomice |
AU2466895A (en) | 1995-04-28 | 1996-11-18 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
AU744146B2 (en) | 1996-09-26 | 2002-02-14 | Chugai Seiyaku Kabushiki Kaisha | Antibody against human parathormone related peptides |
US5986065A (en) * | 1997-03-10 | 1999-11-16 | Sunol Molecular Corporation | Antibodies for inhibiting blood coagulation and methods of use thereof |
JP3998419B2 (ja) * | 1998-04-03 | 2007-10-24 | 中外製薬株式会社 | ヒト組織因子(tf)に対するヒト型化抗体およびヒト型化抗体の作製方法 |
EP0987274A1 (en) * | 1998-09-15 | 2000-03-22 | Hoechst Marion Roussel Deutschland GmbH | Factor VIIa Inhibitors |
-
2000
- 2000-09-29 SK SK444-2002A patent/SK4442002A3/sk unknown
- 2000-09-29 BR BR0014667-6A patent/BR0014667A/pt not_active IP Right Cessation
- 2000-09-29 EP EP10180790A patent/EP2351483A1/en not_active Withdrawn
- 2000-09-29 AT AT00963006T patent/ATE498305T1/de not_active IP Right Cessation
- 2000-09-29 CZ CZ20021035A patent/CZ20021035A3/cs unknown
- 2000-09-29 DK DK00963006.2T patent/DK1222854T3/da active
- 2000-09-29 AU AU74506/00A patent/AU7450600A/en not_active Abandoned
- 2000-09-29 EP EP00963006A patent/EP1222854B1/en not_active Expired - Lifetime
- 2000-09-29 KR KR1020027004130A patent/KR20030008205A/ko not_active Application Discontinuation
- 2000-09-29 WO PCT/JP2000/006802 patent/WO2001024626A1/ja not_active Application Discontinuation
- 2000-09-29 DE DE60045638T patent/DE60045638D1/de not_active Expired - Lifetime
- 2000-09-29 CA CA002388408A patent/CA2388408A1/en not_active Abandoned
- 2000-09-29 PL PL00354961A patent/PL354961A1/xx unknown
- 2000-09-29 JP JP2001527640A patent/JP3859512B2/ja not_active Expired - Fee Related
- 2000-09-29 IL IL14898000A patent/IL148980A0/xx unknown
- 2000-09-29 US US10/089,501 patent/US8062638B1/en not_active Expired - Fee Related
- 2000-09-29 MX MXPA02003278A patent/MXPA02003278A/es unknown
- 2000-09-29 HU HU0203486A patent/HUP0203486A2/hu unknown
-
2002
- 2002-03-21 NO NO20021410A patent/NO20021410L/no not_active Application Discontinuation
-
2011
- 2011-10-04 US US13/252,455 patent/US20120073002A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
MXPA02003278A (es) | 2002-09-02 |
KR20030008205A (ko) | 2003-01-24 |
EP1222854A1 (en) | 2002-07-17 |
US8062638B1 (en) | 2011-11-22 |
IL148980A0 (en) | 2002-11-10 |
EP1222854B1 (en) | 2011-02-16 |
CA2388408A1 (en) | 2001-04-12 |
BR0014667A (pt) | 2002-07-02 |
NO20021410L (no) | 2002-05-24 |
DK1222854T3 (da) | 2011-03-14 |
EP1222854A4 (en) | 2006-07-05 |
US20120073002A1 (en) | 2012-03-22 |
PL354961A1 (en) | 2004-03-22 |
ATE498305T1 (de) | 2011-03-15 |
EP2351483A1 (en) | 2011-08-03 |
DE60045638D1 (de) | 2011-03-31 |
NO20021410D0 (no) | 2002-03-21 |
CZ20021035A3 (cs) | 2002-08-14 |
SK4442002A3 (en) | 2003-04-01 |
AU7450600A (en) | 2001-05-10 |
JP3859512B2 (ja) | 2006-12-20 |
WO2001024626A1 (fr) | 2001-04-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG146666A1 (en) | Methods of using regenerative cells in the treatment of peripheral vascular disease and related disorders | |
DE60107065D1 (de) | Behandlung des kongestiven herzversagens durch vorbehandeltes autologes blut | |
ATE454166T1 (de) | Behandlung von patienten die eine knochenmarktransplantation oder eine transplantation peripherer blutstammzellen erhalten mit anti-cd20 antikörpern | |
DE69634828D1 (de) | Auffindbare künstliche bioimplantate | |
DE60236413D1 (de) | Inhibitoren von hmgb1 zur behandlung von gewebekrankheiten | |
BR0111300A (pt) | Implante de neurotoxina | |
BR9807916A (pt) | Conjunto de dispositivo biomédico, método para inibir substancialmente a reestenose em um vaso sanguìneo de um paciente, método para fabricar um conjunto de dispositivo biomédico. | |
CY1107640T1 (el) | Μεθοδος για πιστοποιηση παραγοντων για τη θεραπεια διαβητη | |
NO20052505L (no) | Ny bruk av dextran-sulfat | |
ATE277628T1 (de) | Behandlung von hematopoietischen zellen mit cxcr4 agonisten | |
HUP0203486A2 (hu) | Véralvadással összefüggő betegségek megelőzése és kezelése | |
DE50014532D1 (de) | Verwendung von (+)-tramadol, o-demethyltramadol, o-desmethyl-n-mono-desmethyl-tramadol zur therapie der harninkontinenz | |
KR950700079A (ko) | 이식체-대-숙주 질환을 억제하기 위한 인터루킨-10의 용도(Use of interleukin-10 to suppress graft-vs. -host disease) | |
DE602004024221D1 (de) | Behandlung von entzündlichen darmerkrankungen mit 2-methylen-19-nor-vitamin d verbindungen | |
CO5280202A1 (es) | Metodos de tratamiento y metodos de rastreo de farmacos | |
DE50103012D1 (de) | Verwendung von hyaluronidase zur prophylaxe und behandlung von herz-kreislauf-erkrankungen | |
HUP9903679A2 (hu) | Olanzapin alkalmazása bipoláris zavar kezelésére szolgáló gyógyszerkészítmények előállítására | |
ATE546548T1 (de) | Verfahren zur prognose des nutzens einer antioxidationshemmenden therapie zur vorbeugung von herz-kreislauf-erkrankungen bei hyperglykämischen patienten | |
UA31131A (uk) | Спосіб прогнозування післяопераційного перебігу інфекційного ендокардиту | |
Nagami | The woman with a worm in her head: And other true stories of infectious disease | |
DE69832796D1 (de) | Verwendung von mizolastine zur herstellung eines arzneimittels zur behandlung von entzündungen | |
Krizek | Wound and reconstructive problems in advanced disease | |
WO2004037120A3 (en) | Implantable medical devices using zinc | |
EA200300076A1 (ru) | Способ профилактики и лечения атеросклероза | |
ATE235908T1 (de) | Verwendung von pentosan polysulfat zur behandlung von narben in chronischer fortschreitender gefässerkrankungen |